Shih-Duo Hsu Hung

Shih-Duo Hsu Hung

Auto-generated profile, based on publicly available information

Shih-Duo Hsu Hung

Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Ongoing clinical trial of phosphorylation-associated small molecule drugs and anti-PD-1/PD-L1 combination

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
The biological function of PD-1 on immune cells and cancer cells

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.

15 March 2024
Verified
Other
Open access
TLTe-An Lee
Te-An Lee
ETEn-Yun Tsai
En-Yun Tsai
SLShou-Hou Liu
Shou-Hou Liu
SHShih-Duo Hsu Hung
Shih-Duo Hsu Hung
SCShing-Jyh Chang
Shing-Jyh Chang
CLChia-Wei Li
Chia-Wei Li
Ongoing clinical trial of SHP-2 specific small molecule drugs on multiple cancers